|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,288.00 ILa | +1.37% |
|
+7.42% | +1.24% |
| 06-01 | Kamada Announces FDA Approval of Its New In-House Rabies Virus Neutralization Testing Laboratory | CI |
| 05-13 | Kamada Ltd., Q1 2026 Earnings Call, May 13, 2026 |
Company Valuation: Kamada Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,302 | - | - |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | -0.13% | - | - |
| Enterprise Value (EV) | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,302 | 1,302 | 1,302 |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | -0.13% | 0% | 0% |
| P/E | - | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.7x | 1.31x | 2.51x | 2.17x | 2.35x | 2.23x | 2.03x | 1.82x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.23x | 2.03x | 1.82x |
| EV / EBITDA | - | - | 0x | 0x | 0x | 8.66x | 7.17x | 6.88x |
| EV / EBIT | -0x | 0x | 0x | 0x | 0x | 13x | 10.4x | 8.59x |
| EV / FCF | -0x | - | -0x | 0x | 0x | 17.2x | 12.4x | 9.77x |
| FCF Yield | -4.52% | - | -0.43% | 10.5% | 3.73% | 5.8% | 8.09% | 10.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 340.3 | 469.1 | 510.9 | 586.9 | 555.7 | 584.7 | 641.9 | 716.6 |
| EBITDA 1 | - | - | 86.36 | 124.5 | 129.3 | 150.3 | 181.7 | 189.2 |
| EBIT 1 | -2.286 | 16.44 | 36.08 | 73.11 | 80.79 | 100 | 125.1 | 151.5 |
| Net income 1 | -7.323 | -8.417 | 29.7 | 52.73 | 62.2 | 72.01 | 103.6 | 127.2 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 20.55 | 13.72 | 22.27 | 22.11 | 22.60 | 22.57 | 22.57 | 22.57 |
| Nbr of stocks (in thousands) | 44,786 | 44,826 | 57,476 | 57,492 | 57,682 | 57,686 | - | - |
| Announcement Date | 3/15/22 | 3/15/23 | 3/6/24 | 3/5/25 | 3/11/26 | - | - | - |
1ILS in Million2
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 435M | |
| 16.94x | 3.69x | 9.97x | 0.6% | 66.56B | |
| 28.53x | 5.87x | 17.23x | 0.55% | 57.64B | |
| 34.88x | 11.82x | 22.38x | -.--% | 42.24B | |
| -43.93x | 3.11x | 9.2x | 3.49% | 39.09B | |
| 34.9x | 3.71x | 11.39x | -.--% | 31.91B | |
| -9.24x | 13.4x | -8.22x | -.--% | 31.65B | |
| 16.96x | 3.25x | 9.83x | -.--% | 23.35B | |
| 53.7x | 5.97x | 40.99x | -.--% | 18.92B | |
| 26.89x | 5.5x | 14.75x | -.--% | 17.17B | |
| Average | 17.74x | 6.26x | 14.17x | 0.52% | 32.9B | |
| Weighted average by Cap. | 15.90x | 6.18x | 13.16x | 0.63% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- KMDA Stock
- Valuation Kamada Ltd.
Select your edition
All financial news and data tailored to specific country editions
